Document Type

Paper

Publication Date

3-17-2014

Abstract

CXCR4 is a co-receptor on the surface of immune cells that has been proven to facilitate the entry of HIV into the cells. Within the last 15 years the CXCR4 and CCR5 coreceptors have influenced new therapeutic approaches to the treatment of HIV via fusion inhibitor drugs that target these receptors. Our aim is to develop new antagonists for the CXCR4 coreceptor. Specifically, the goal was the synthesis of Propyl Cross-Bridged, linked analogues of the known CXCR4 antagonist AMD-3100.

Comments

Source: 2014 Spring National Meeting of the American Chemical Society, Dallas, TX

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.